Description

ERLOTERO 150 MG (1X30)

Indications

ERLOTERO 150 MG is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) in patients who have previously received chemotherapy or targeted therapy. It is particularly effective in cases where the cancer is characterized by specific mutations, such as the epidermal growth factor receptor (EGFR) mutation. Additionally, ERLOTERO may be used in the treatment of other malignancies as determined by the healthcare provider based on individual patient circumstances and tumor characteristics.

Mechanism of Action

ERLOTERO contains erlotinib as its active ingredient, which is a potent inhibitor of the EGFR tyrosine kinase. By binding to the tyrosine kinase domain of the EGFR, erlotinib prevents the phosphorylation of downstream signaling pathways that promote cell proliferation and survival. This inhibition leads to a reduction in tumor growth and can induce apoptosis in cancer cells that depend on EGFR signaling for survival. The specificity of erlotinib for EGFR makes it a targeted therapy, minimizing damage to normal cells compared to conventional chemotherapeutics.

Pharmacological Properties

ERLOTERO exhibits a pharmacokinetic profile characterized by rapid absorption and a peak plasma concentration reached within 4 hours post-administration. The drug has a bioavailability of approximately 60% when taken orally. It is primarily metabolized in the liver by cytochrome P450 enzymes, particularly CYP3A4 and CYP1A1. The elimination half-life of erlotinib is about 36 hours, allowing for once-daily dosing. The drug is approximately 95% bound to plasma proteins, which influences its distribution and therapeutic efficacy.

Contraindications

ERLOTERO is contraindicated in patients with known hypersensitivity to erlotinib or any of its excipients. It should not be administered to individuals with severe hepatic impairment, as the metabolism of the drug may be significantly altered, leading to increased toxicity. Additionally, it is not recommended for use during pregnancy due to potential teratogenic effects, and breastfeeding is also contraindicated while on this medication.

Side Effects

The use of ERLOTERO may be associated with several side effects, some of which may require medical attention. Common side effects include:

• Diarrhea
• Rash
• Fatigue
• Nausea
• Loss of appetite
• Dry skin

Serious adverse effects can occur, including interstitial lung disease, liver function abnormalities, and gastrointestinal perforation. Patients should be monitored closely for any signs of severe reactions, and appropriate management should be initiated as necessary.

Dosage and Administration

The recommended dosage of ERLOTERO is 150 mg taken orally once daily, with or without food. It is essential for patients to take the medication at the same time each day to maintain consistent drug levels in the bloodstream. In cases of missed doses, patients should take the missed dose as soon as they remember, unless it is close to the time of the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule should be resumed. Dose adjustments may be necessary based on the patient’s tolerance and the presence of side effects.

Interactions

ERLOTERO may interact with several medications, which can either increase the risk of adverse effects or decrease the therapeutic efficacy of erlotinib. Notable drug interactions include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase erlotinib levels, leading to enhanced toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, St. John’s wort) may decrease erlotinib levels, reducing its effectiveness.
• Antacids and proton pump inhibitors may alter the absorption of erlotinib, and their use should be discussed with a healthcare provider.

Patients are advised to inform their healthcare providers of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before starting treatment with ERLOTERO, healthcare providers should conduct a thorough assessment of the patient’s medical history, including any history of lung disease or liver impairment. Regular monitoring of liver function tests is recommended during treatment, as hepatotoxicity can occur. Patients should also be monitored for signs of interstitial lung disease, especially if they present with respiratory symptoms such as cough or difficulty breathing. It is crucial to ensure that patients are aware of the potential side effects and the importance of reporting any unusual symptoms promptly.

Clinical Studies

Clinical studies have demonstrated the efficacy of ERLOTERO in improving overall survival rates in patients with NSCLC harboring EGFR mutations. In a pivotal phase III trial, patients treated with erlotinib showed a significant improvement in progression-free survival compared to those receiving standard chemotherapy. The study also highlighted the favorable safety profile of erlotinib, with manageable side effects that were consistent with previous findings. Ongoing research continues to explore the potential of erlotinib in combination with other therapeutic agents to enhance treatment outcomes in various malignancies.

Conclusion

ERLOTERO 150 MG is a targeted therapy that plays a crucial role in the management of non-small cell lung cancer, particularly in patients with specific genetic mutations. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable option in oncology. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should engage in open communication with their healthcare providers to optimize their treatment plans and address any concerns that may arise during therapy.